Skip to main content

Search articles in Clinical Research

Found 248 articles

  • Thermo Fisher Scientific to Help Advance Myeloid C

    Thermo Fisher Scientific to Help Advance Myeloid Cancer Clinical Research and Treatment Utilizing Next Generation Sequencing Technology

    • 12 Jul 2024
    • Editor

    To help accelerate research into new treatments for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, is partnering with the National Cancer Institute (NCI) – part of the National Institutes of Health – on the myeloMATCH (Molecular Analysis for Therapy Choice) precision medicine umbrella trial.

  • ICON recognised for leadership position in clinica

    ICON recognised for leadership position in clinical research industry and as socially responsible employer

    • 11 Jul 2024
    • Editor

    ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addition to its efforts in inclusion, sustainability and as an employer of choice.

  • Cambridge Cognition secures Innovate UK grant to c

    Cambridge Cognition secures Innovate UK grant to collect multimodal data with a large patient sample in the Bio-Hermes 2 project

    • 11 Jul 2024
    • Editor

    Cambridge Cognition, a leading provider of digital health solutions for brain health assessments has been included in the Bio-Hermes 2 project for its voice and touch-screen cognitive assessments, funded by the UK’s innovation agency, Innovate UK.

  • Allucent Awarded 5-Year BARDA Agreement Aimed at E

    Allucent Awarded 5-Year BARDA Agreement Aimed at Enhancing and Accelerating Decentralized Clinical Trials for Medical Countermeasure Development

    • 9 Jul 2024
    • Editor

    Allucent, a global mid-sized clinical research organization (CRO), announced today that it has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for its new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.

  • Thermo Fisher Scientific Expands Clinical Research

    Thermo Fisher Scientific Expands Clinical Research Laboratory in Kentucky

    • 28 Jun 2024
    • Editor

    The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today announced the expansion of its central laboratory operations in Kentucky dedicated to accelerating pharmaceutical and biotech customers’ delivery of safe, effective medicines to patients.

  • Parexel and Palantir Expand Collaboration to Accel

    Parexel and Palantir Expand Collaboration to Accelerate Clinical Data Delivery and Power Clinical Outcomes for Patients

    • 26 Jun 2024
    • Editor

    Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, and Palantir Technologies Inc. (NYSE: PLTR) (Palantir), a leading builder of Artificial Intelligence (AI) systems, today announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers.

  • Thermo Fisher Scientific Expands Clinical Research

    Thermo Fisher Scientific Expands Clinical Research Laboratory in Wisconsin

    • 19 Jun 2024
    • Editor

    The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, today unveiled a new clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin.

  • Labcorp Launches Global Trial Connect to Accelerat

    Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

    • 18 Jun 2024
    • Editor

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.

  • Moderna's Investigational Therapeutic for Methylma

    Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program

    • 7 Jun 2024
    • Editor

    Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. mRNA-3705 is an investigational therapeutic for methylmalonic acidemia (MMA) due to methylmalonic-CoA mutase (MUT) deficiency.

  • AbbVie Advances Oncology Pipeline With Start of Mu

    AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

    • 6 Jun 2024
    • Editor

    AbbVie (NYSE: ABBV) today announced that the first patient has been treated with investigational ABBV-383 in the CERVINO Phase 3 study.

  • Gilead’s Seladelpar Demonstrated a Sustained and C

    Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

    • 6 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE study of investigational seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease.

  • Gilead Sciences Advances Enrollment in Collaborati

    Gilead Sciences Advances Enrollment in Collaborative Studies to Assess Twice-Yearly HIV Prevention Option for Both Cisgender Women in the U.S. and People Who Inject Drugs in the U.S.

    • 5 Jun 2024
    • Editor

    Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company is advancing enrollment in two groundbreaking collaborative studies to evaluate the tolerability of an investigational long-acting HIV prevention option in groups of people in the United States who are disproportionately affected by HIV but who are often underrepresented in HIV clinical trials.

  • Thermo Fisher Scientific Introduces Innovative Mas

    Thermo Fisher Scientific Introduces Innovative Mass Spectrometer to Advance Clinical Research

    • 4 Jun 2024
    • Editor

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use to allow researchers to advance their translational omics research and make breakthrough discoveries more efficiently.

  • New results from rilzabrutinib phase 2 study show

    New results from rilzabrutinib phase 2 study show potential to be first advanced oral treatment for moderate-to-severe asthma

    • 23 May 2024
    • Editor

    Encouraging results from a phase 2 study showed that treatment with oral rilzabrutinib at both high dose and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma.

  • GSK announces positive results from phase III seve

    GSK announces positive results from phase III severe asthma trials of depemokimab

    • 21 May 2024
    • Editor

    GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count.

  • Allucent Receives BARDA-Funded Project NextGen Awa

    Allucent Receives BARDA-Funded Project NextGen Award to Support a COVID-19 Vaccine Decentralized Clinical Trial

    • 16 May 2024
    • Editor

    Allucent, a global mid-sized clinical research organization (CRO), announced today that it received a project award valued at $25.5 million through the Rapid Response Partnership Vehicle (RRPV) Consortium to conduct its Decentralized Home Focus COVID-19 Trial.

  • Roche reports positive Phase Ib results for its du

    Roche reports positive Phase Ib results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity

    • 16 May 2024
    • Editor

    Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase I clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes.

  • SUPERNOVA Phase III trial of sipavibart long-actin

    SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population

    • 16 May 2024
    • Editor

    Positive high-level results from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial showed AstraZeneca’s sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a statistically significant reduction in the incidence of symptomatic COVID‑19 compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population.

  • Recce Pharmaceuticals Reports Positive Preclinical

    Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study

    • 14 May 2024
    • Editor

    Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a preclinical pilot study evaluating nebulized RECCE® 327 (R327) for the treatment of lung infections in a mouse model.

  • Kite and Arcellx Continue Momentum with Advances i

    Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

    • 10 May 2024
    • Editor

    Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.